e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Safety of and interactions between current treatments for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID
Niels Seersholm (Copenhagen, Denmark), Niels Seersholm, Robert Sandhaus, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, James Stocks, Michael Tortorici, Tanja Rosenberg, Oliver Vit, Martin Bexon, Jonathan Edelman, N. Gerard McElvaney
Source:
International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Session:
Safety of and interactions between current treatments for asthma and COPD
Session type:
Thematic Poster Session
Number:
999
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Niels Seersholm (Copenhagen, Denmark), Niels Seersholm, Robert Sandhaus, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, James Stocks, Michael Tortorici, Tanja Rosenberg, Oliver Vit, Martin Bexon, Jonathan Edelman, N. Gerard McElvaney. Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID. Eur Respir J 2015; 46: Suppl. 59, 999
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Long-term efficacy of A
1
-PI therapy in RAPID and its extension study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
LATE-BREAKING ABSTRACT: Long-term efficacy of A1-PI therapy in RAPID and RAPID extension trials
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Integrated safety across six clinical trials of alpha-1 augmentation therapy
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Safety of biweekly a
1
-antitrypsin treatment in the RAPID programme
Source: Eur Respir J, 52 (5) 1800897; 10.1183/13993003.00897-2018
Year: 2018
Safety and tolerability of acute dosing of beta-blockers in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Management of selexipag interruptions in the GRIPHON study
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016
Pharmacological treatment of COPD in the on-sint cohort
Source: International Congress 2014 – COPD exacerbations
Year: 2014
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM)
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
Evaluation of methotrexate in the treatment of severe asthma
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept